摘要
目的 观察血管内皮生长因子抑制剂Avastin玻璃体腔注射治疗白内障术后黄斑囊样水肿的疗效.方法 对2013年1月至2014年1月在深圳市眼科医院就诊的11例白内障术后黄斑囊样水肿患者行Avastin玻璃体腔注射1.5 mg,治疗后随访3个月,对比分析治疗前后最佳矫正视力、眼压变化、人工晶状体情况及眼底情况、Zeiss stratus OCT测量黄斑中心凹视网膜厚度.结果 行Avastin玻璃体腔注射治疗后,患者视力明显提高,治疗前最佳矫正视力0.05～0.3,治疗后最佳矫正视力0.6～1.0.随访期内未见眼压异常变化,人工晶状体未见异常,未见与药物有关的视网膜毒性反应.OCT测量黄斑中心凹视网膜厚度治疗前平均（563.37±147.86） μm,治疗后1个月平均厚度（208.47±86.34） μm,至末次随访平均厚度（202.12±78.27）Iμm,治疗前后比较差异有统计学意义（P＜0.05）.结论 Avstin玻璃体腔注射治疗白内障术后黄斑囊样水肿可有效提高患者视力,黄斑水肿明显消退.
Objective To investigate the effect of intravitreous injection of Avastin for cystoid macular edema after cataract surgery.Methods Eleven cases with cystoid macular edema after cataract surgery were performed intravitreous injection of Avastin（1.5mg）and follow up 3 months.The pre-operative and post-operative best corrected visual acuity（BCVA）,intraocular pressure（IOP）,slim lamp and fundus examination were recorded and analyzed at different time point.At the same time,optical coherence tomography（OCT）examinations were performed.Results The pre-op BCVA in all cases were improved after intravitreous injection of Avastin.During the follow-up,no significant changes in IOP and anterior segment.The retina toxicity reactions relevant to Avastin were nothing.The pre-injection central macular thickness was（563.37±147.86）μtm,while the post-op central macular thickness was（208.47±86.34）μm at 1 month post-injection and（202.12±78.27）μm at 3 months post-injection.There was significant difference between the thickness pre-injection and post-injection.Conclusions The intravitreous injection of Avastin can relieve macular edema and improve BCVA for cystoid macular edema after cataract surgery.
出处
《中国实用眼科杂志》
CSCD
北大核心
2014年第10期1194-1196,共3页
Chinese Journal of Practical Ophthalmology
